IP Verse

Compounds For Use In The Treatment Of Erbb2+ Brain Cancer - EP3400943

The patent EP3400943 was granted to Array Biopharma on Dec 2, 2020. The application was originally filed on Mar 25, 2013 under application number EP18162971A. The patent is currently recorded with a legal status of "Revoked".

EP3400943

ARRAY BIOPHARMA
Application Number
EP18162971A
Filing Date
Mar 25, 2013
Status
Revoked
Feb 8, 2025
Grant Date
Dec 2, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZSep 1, 2021ADMISSIBLE
TEVA PHARMACEUTICALSSep 1, 2021ADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2007059257
OPPOSITIONWO2007059257
OPPOSITIONWO2013142875
SEARCHWO2007059257
SEARCHWO2009042618
SEARCHWO2013056108

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- KOCH; KEVIN, "ARRY-380: A Selective, Oral HER2 Inhibitor for the Treatment of Solid Tumors", American Association of Cancer Research 102nd Annual Meeting, (20110403), URL: http://www.arraybiopharma.com/_documents/Publication/ PubAttachment462.pdf-
DESCRIPTION- ZHOU, RONG et al., "pH-Dependent Dissolution in Vitro and Absorption in Vivo of Weakly Basic Drugs: Development of a Canine Model", Pharm. Res., (20050200), vol. 22, no. 2, doi:doi:10.1007/s11095-004-1185-3, pages 188 - 192, XP019370779
OPPOSITION- Koch Kevin, "ARRY-380: A Selective, Oral HER2 inhibitor for the Treatment of Solid Tumors", pages 1 - 29, URL: http://www.arraybiopharma.com/_documents/Publication/PubAttachment462.pdf, (20130214), XP002692140-
OPPOSITION- Lindemann C, "Amorphous Dispersion Development of ARRY-380, an ErbB2 Selective Inhibitor", Array, (20121017), pages 1 - 1, XP055839901-
OPPOSITION- Giri Tapan Kumar, Et Al, "A novel and alternative approach to controlled release drug delivery system based on solid dispersion technique", Cairo University. Faculty of Pharmacy. Bulletin, Cairo University, Faculty of Pharmacy, Egypt (Arab Republic of Egypt), Egypt (Arab Republic of Egypt), (20121201), vol. 50, no. 2, doi:10.1016/j.bfopcu.2012.07.002, ISSN 1110-0931, pages 147 - 159, XP055839894
OPPOSITION- Zielinski C., Gralow J., Martin M., "Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?", Annals of Oncology, Kluwer Dordrecht, NL, NL, (20101101), vol. 21, no. 11, doi:10.1093/annonc/mdq069, ISSN 0923-7534, pages 2145 - 2152, XP055839896
OPPOSITION- Victoria Dinkel, Anderson Deborah, Winski Shannon, Winkler James, Koch Kevin, Lee Patrice A., "Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice", Cancer research, American Association for Cancer Research, (20120415), vol. 72, no. 8 Supplement, doi:10.1158/1538-7445.AM2012-852, ISSN 0008-5472, pages 852 - 852, XP055225281
OPPOSITION- Srinarong Parinda, De Waard Hans, Frijlink Henderik W, Hinrichs Wouter Lj, "Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations", Expert Opinion on Drug Delivery, Informa Healthcare, GB, GB, (20110901), vol. 8, no. 9, doi:10.1517/17425247.2011.598147, ISSN 1742-5247, pages 1121 - 1140, XP055839893
SEARCH- KOCH KEVIN, "ARRY-380: A Selective, Oral HER2 inhibitor for the Treatment of Solid Tumors", INTERNET CITATION, (20110403), pages 1 - 29, URL: http://www.arraybiopharma.com/_documents/Publication/PubAttachment462.pdf, (20130214), XP002692140 [XD] 1-5,11,12,15 * Slides 4, 12-17,19, 27, 28 * [I] 6-10,13,14-
SEARCH- S L Moulder ET AL, "Arry-380, a selective HER2 inhibitor: From drug design to clinical evaluation", EORTC Conference, (20110114), page 1, URL: http://www.arraybiopharma.com/_documents/Publication/PubAttachment491.pdf, (20130524), XP055064078 [A] 1-15 * the whole document *
SEARCH- VICTORIA DINKEL ET AL, "Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice", CANCER RESEARCH, US, (20120415), vol. 72, no. 8 Supplement, doi:10.1158/1538-7445.AM2012-852, ISSN 0008-5472, pages 852 - 852, XP055225281 [IP] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents